Cognitive-motor interference during gait in patients with multiple sclerosis: a mixed methods systematic review

ConclusionsCMI should be assessed in MS with a standardised dual task such as the Verbal Fluency task while walking, with measurements of the double support time and the effect on the cognitive task. The clinical usefulness of CMI in the assessment of patients with MS is discussed.
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research

Related Links:

We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
Source: Journal of Neurology - Category: Neurology Source Type: research
A critical role for IL-17, a cytokine produced by T helper 17 (Th17) cells, has been indicated in the pathogenesis of chronic inflammatory and autoimmune diseases. A positive effect of blockade of IL-17 secreted by autoreactive T cells has been shown in various inflammatory diseases. Several cytokines, whose production is affected by environmental factors, control Th17 differentiation and its maintenance in tissues during chronic inflammation. The roles of IL-17 in the pathogenesis of chronic neuroinflammatory conditions, multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), Alzheimer's disease, and isc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractMultiple sclerosis (MS) is a neuroinflammatory disease in which unresolved and uncontrolled inflammation disrupts normal cellular homeostasis and leads to a pathological disease state. It has long been recognized that endogenously derived metabolic by-products of omega fatty acids, known as specialized pro-resolving lipid mediators (SPMs), are instrumental in resolving the pathologic inflammation. However, there is minimal data available on the functional status of SPMs in MS, despite the fact that MS presents a classical model of chronic inflammation. Studies to date indicate that dysfunction of the SPM biosynthet...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
The U.S. Food and Drug Administration has extended the review period for Novartis AG's multiple sclerosis drug ofatumumab by three months, the company said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This study aims to identify reliable and objective gait-based biomarkers to monitor progressive multiple sclerosis (MS) in clinical s...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Authors: Smolders J, Fransen NL, Hsiao CC, Hamann J, Huitinga I Abstract INTRODUCTION: Multiple sclerosis (MS) is characterized by inflammatory attacks of infiltrating leukocytes at onset but evolves into a smoldering, progressive disease within the central nervous system at its later stages. The authors discuss the contribution of white matter lesions to the pathology of advanced MS, thereby paying particular attention to the role of T cells. AREAS COVERED: Diagnostic biopsy and autopsy studies of white matter lesions in early MS show different pathological patterns of demyelination and leukocyte infiltration. Bra...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Publication date: Available online 2 June 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Virginia Meca-Lallana, Clara Aguirre, Laura Cardeñoso, Teresa Alarcon, Angels Figuerola-Tejerina, Beatriz del Río, Miguel Ruiz Álvarez, José Vivancos
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Condition:   Secondary Progressive Multiple Sclerosis Interventions:   Drug: SAR442168;   Drug: Placebo to match SAR442168 Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis Intervention:   Device: DreaMS Sponsor:   Research Center for Clinical Neuroimmunology and Neuroscience Basel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Secondary Progressive Multiple Sclerosis Interventions:   Drug: SAR442168;   Drug: Placebo to match SAR442168 Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Multiple Sclerosis | Neurology | Neuroscience | Study